| Drug Name |
Opicapone |
| Drug ID |
BADD_D02576 |
| Description |
Opicapone is a potent, reversible, and peripherally-acting third-generation inhibitor of catechol-o-methyltransferase (COMT), an enzyme involved in the breakdown of various catecholamines including dopamine.[A36938, A203048] Many patients with Parkinson’s disease treated with levodopa plus a dopa decarboxylase (DDC) inhibitor (eg carbidopa) experience motor complications over time, which calls for the management of these symptoms through the use of a dopamine agonist, a monoamine oxidase B inhibitor (selegiline, rasagiline), a _catechol-O-methyl transferase (COMT)_ inhibitor, or amantadine, or using a modified-release formulation of levodopa.[L2336]
Opicapone is used for adjunct therapy to levodopa and carbidopa in adult patients with Parkinson's disease and end-of-dose motor fluctuations. Opicapone was approved for use by the European Commission in June 2016 [L2339] and the FDA in April 2020.[L13772] It is marketed under the brand name Ongentys as once-daily oral capsules. Exhibiting a long duration of action that exceeds 24 hours, opicapone can be administered once-daily [L2336] and demonstrates the lowest risk for cytotoxicity compared to other catechol-O-methyltransferase inhibitors.[A203048] |
| Indications and Usage |
Opicapone is indicated as adjunctive therapy in adults with Parkinson’s disease and end-of-dose motor fluctuations or “off” episodes whose symptoms cannot be stabilized on the combination therapy of levodopa and DOPA decarboxylase inhibitor (e.g., carbidopa).[L2343, L13772] |
| Marketing Status |
approved; investigational |
| ATC Code |
N04BX04 |
| DrugBank ID |
DB11632
|
| KEGG ID |
D10825
|
| MeSH ID |
C549349
|
| PubChem ID |
135565903
|
| TTD Drug ID |
D01SGK
|
| NDC Product Code |
70370-3025; 45941-3057; 11014-0421; 17337-0088; 70370-3050 |
| UNII |
Y5929UIJ5N
|
| Synonyms |
opicapone | 2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine 1-oxide | ongentys | BIA 9-1067 |
